Talk:Idarucizumab

This is the talk page for discussing improvements to the Idarucizumab article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Idarucizumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Wiki Education assignment: PHMD 2040 Service - Learning Fall 2023

This article was the subject of a Wiki Education Foundation-supported course assignment, between 31 May 2023 and 29 December 2023. Further details are available on the course page. Student editor(s): Balugaa3 (article contribs).

— Assignment last updated by Balugaa3 (talk) 21:23, 30 April 2024 (UTC)[reply]

New Sections

I will be adding information for 3 new sections: mechanism of action, medical uses and adverse effects. The sources I'm using are DailyMed, 2 systematic reviews by van der Horst et. al and Thibault et. al, and clinical guidelines from Canada and the US. --Balugaa3 (talk) 05:29, 1 May 2024 (UTC)[reply]

Also, a new section called “Pharmacokinetics” should be added as there is evidence showing that marked decrease in renal function may decrease the effectiveness of idarucizumab. Dabigatran isn’t usually prescribed to those with low eGFR or severe CKD, but these findings are still relevant to patients on dabigatran who experience a sudden decline in renal function, like an acute kidney injury. The paper “Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis” by Athavale et. al (PMID: 32267185) illustrates this. Balugaa3 (talk) 20:13, 1 May 2024 (UTC)[reply]